The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.
Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial.
Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center.
Dosing is expected to start in 1H of 2022.
Additionally, to streamline operations, the Company has closed its Boston office. Alaunos will be headquartered in Houston.
Price Action: ZIOP shares are up 1.02% at $0.88 during the market session on the last check Wednesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.